H. Lee Moffitt Cancer Center and Research Institute: Leukemia trials

The registry lists 26 Leukemia studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 9Phase 2 19Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaCompletedNCT03575325Phase 2Results posted
• Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaTerminatedNCT03514017Phase 2Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of RuxolitinibCompletedNCT01776723Phase 1/2Results posted
• Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT01497496Phase 2Results posted
• Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLCompletedNCT01496976Phase 2Results posted
• Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)TerminatedNCT01090973Phase 2Results posted
• CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT00955916Phase 2Results posted
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
• Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction ChemotherapyCompletedNCT00387647Phase 2Results posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell ImmunotherapyCompletedNCT05763563Not applicable
• Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03760523Phase 1
• A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1
• Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
• Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)CompletedNCT01324180Phase 1
• Arsenic Trioxide for Induction Therapy of Adult Patients With LeukemiaTerminatedNCT00006092Phase 2
• Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow TransplantTerminatedNCT00005852Phase 2
• Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 2
• A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and EtoposideCompletedNCT00005793Phase 1/2
• Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationTerminatedNCT00005641Phase 2
• Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)CompletedNCT00005626Phase 2
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00005622Phase 2